Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35468945

Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Leukemia
Publication date
2022 Jun
First author
Pennesi E

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Pennesi E
      type
      Author
    2. name
      Michels N
      type
      Author
    3. name
      Brivio E
      type
      Author
    4. name
      van der Velden VHJ
      type
      Author
    5. name
      Jiang Y
      type
      Author
    6. name
      Thano A
      type
      Author
    7. name
      Ammerlaan AJC
      type
      Author
    8. name
      Boer JM
      type
      Author
    9. name
      Beverloo HB
      type
      Author
    10. name
      Sleight B
      type
      Author
    11. name
      Chen Y
      type
      Author
    12. name
      Vormoor-Bürger B
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Pennesi E
      type
      Author
    2. name
      Michels N
      type
      Author
    3. name
      Brivio E
      type
      Author
    4. name
      van der Velden VHJ
      type
      Author
    5. name
      Jiang Y
      type
      Author
    6. name
      Thano A
      type
      Author
    7. name
      Ammerlaan AJC
      type
      Author
    8. name
      Boer JM
      type
      Author
    9. name
      Beverloo HB
      type
      Author
    10. name
      Sleight B
      type
      Author
    11. name
      Chen Y
      type
      Author
    12. name
      Vormoor-Bürger B
      type
      Author
    bibliography ids
    1. nci-bib-7c48fb9e381ab04f86a0d115
    book metadata
    content sha256
    70220025624c8c38e704d21e44e322faa3e725aca18f1aa4f6ec8da1f89012dc
    document type
    citation
    dois
    1. 10.1038/s41375-022-01576-3
    electronic publication date
    display
    2022 Apr 25
    precision
    day
    year
    2022
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:35468945
    immutable id
    pubmed:35468945@70220025624c8c38e704d21e44e322faa3e725aca18f1aa4f6ec8da1f89012dc
    journal
    abbreviation
    Leukemia
    issn electronic
    1476-5551
    issn print
    0887-6924
    issue
    6
    name
    Leukemia
    nlm unique id
    8704895
    pages
    1516-1524
    volume
    36
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      35468945
      provenance
      batch id
      9d150d55960e0c12aada
      provider
      NCBI PubMed ESummary
      record sha256
      c2251f7f095bd7703769cbed5d7819a25e30c8adc816c241eb04b5a45497be88
      response sha256
      2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
      retrieved at
      2026-09-09T23:48:09.820498+00:00
      publication date
      display
      2022 Jun
      precision
      month
      year
      2022
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/35468945/
      title
      Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.

      Preserved source evidence · Not medical advice